GangaGen

About:

GangaGen is a clinical-stage biotechnology company focused on developing novel therapeutic proteins

Website: http://gangagen.com/

Top Investors: CARB-X, ATEL Growth Capital

Description:

GangaGen, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutic proteins targeting infectious diseases in areas of high unmet need such as MRSA and other drug resistant bacteria. Using a proprietary platform, GangaGen is developing highly-specific therapeutic proteins called ectolysins to target clinically meaningful types of bacteria. The company’s lead ectolysin, P128, is a recombinant protein that binds to and kills Staphylococcus, including methicillin-resistant strains of S. aureus (MRSA).